trending Market Intelligence /marketintelligence/en/news-insights/trending/on7UVhf2yPQugL6W36ARMQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aptose Biosciences closes $74.2M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aptose Biosciences closes $74.2M common stock offering

Aptose Biosciences Inc. closed its offering of 18,543,750 common shares priced at $4 per share.

The number of shares sold includes the full exercise of underwriters of their option to buy additional shares.

Gross proceeds were about $74.2 million.

Piper Jaffray & Co. acted as sole active book-running manager for the offering, while Canaccord Genuity acted as passive book-running manager. Oppenheimer & Co. was lead manager, while JonesTrading Institutional Services LLC was co-manager for the offer.

Toronto-based Aptose Biosciences develops personalized therapies for cancer in the U.S. Its drug candidate APTO-253 is in a phase 1b clinical trial for treating patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome.